Entry Point Capital, LLC Biomarin Pharmaceutical Inc Transaction History
Entry Point Capital, LLC
- $68.4 Billion
- Q2 2024
Shares
1 transactions
Others Institutions Holding BMRN
# of Institutions
622Shares Held
183MCall Options Held
1.41MPut Options Held
1.31M-
Black Rock Inc. New York, NY22.7MShares$1.52 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA19MShares$1.27 Billion0.03% of portfolio
-
Primecap Management CO Pasadena, CA18.8MShares$1.26 Billion1.14% of portfolio
-
Dodge & Cox San Francisco, CA13.9MShares$933 Million0.72% of portfolio
-
Capital Research Global Investors Los Angeles, CA9.69MShares$649 Million0.18% of portfolio
About BIOMARIN PHARMACEUTICAL INC
- Ticker BMRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,824,000
- Market Cap $12.4B
- Description
- BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...